Zantac®, the brand name form of the drug ranitidine, has been a popular antacid for decades and heavily prescribed by doctors as well as sold over the counter to millions of adults and infants. Recently, the popular drug has been found to have high levels of the cancer-causing agent N-Nitrosodimethylamine (NDMA), a probable human carcinogen, leading to recalls, investigations, and the potential for life-threatening diseases as a result of taking the drug.
If you, or someone you love, have developed cancer while taking Zantac® or other drugs containing ranitidine, you may be eligible for compensation and Fulmer Sill can guide you through the process.
Testing has found high levels of N-Nitrosodimethylamine (NDMA) in ranitidine. The FDA has established a permissible daily intake limit of NDMA of 96 nanograms (ng). The World Health Organization (WHO) & the International Agency for Research on Cancer (IARC) have classified NDMA as a Group 2A compound, thereby defining it as “probably carcinogenic to humans.” NDMA is a known environmental contaminant found in water and foods, including meats, dairy products & vegetables.
The ranitidine molecule contains both a nitrite and a dimethylamine (DMA) group, which are well known to combine to form NDMA.
The FDA began recalling the popular heartburn drug on September 13th, 2019 and has since recalled 14 generic Ranitidine drugs as well as one name brand, Zantac®, due to their presence of a known carcinogen, NDMA.